CTOs on the Move

Vitro Biopharma

www.vitrobiopharma.com

 
Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Stallergenes

Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioElectronics Corporation

BioElectronics Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Willow Industries

Willow Industries Ozone Systems. Mitigate Mold & Bacteria. Willow systems provide clean and effective solutions to cannabis contamination.

Mango Materials

Mango Materials produces biodegradable plastics from waste biogas (methane) that are economically competitive with conventional, oil-based plastics. Mango Materials produces poly-hydroxyalkanoate (PHA) powder, a valuable biopolymer that is converted into a variety of ecofriendly, plastic products such as children’s toys, electronic casings, water bottles, and food packaging containers. Due to a rising preference for green products, demand for biodegradable and non petroleum-based plastics is growing rapidly. Mango Materials uses affordable methane gas and a process that competes favorably with petroleum-based plastics to produce low-cost, biodegradable plastics.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.